These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 23670557

  • 1. Enhancing the protective immune response against botulism.
    Przedpelski A, Tepp WH, Kroken AR, Fu Z, Kim JJ, Johnson EA, Barbieri JT.
    Infect Immun; 2013 Jul; 81(7):2638-44. PubMed ID: 23670557
    [Abstract] [Full Text] [Related]

  • 2. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
    Henkel JS, Tepp WH, Przedpelski A, Fritz RB, Johnson EA, Barbieri JT.
    Vaccine; 2011 Oct 13; 29(44):7688-95. PubMed ID: 21839134
    [Abstract] [Full Text] [Related]

  • 3. Enhancing toxin-based vaccines against botulism.
    Przedpelski A, Tepp WH, Zuverink M, Johnson EA, Pellet S, Barbieri JT.
    Vaccine; 2018 Feb 01; 36(6):827-832. PubMed ID: 29307477
    [Abstract] [Full Text] [Related]

  • 4. A mutated recombinant subunit vaccine protects mice and guinea pigs against botulinum type A intoxication.
    Yu CH, Song DH, Choi JY, Joe HE, Jeong WH, Hur GH, Shin YK, Jeong ST.
    Hum Vaccin Immunother; 2018 Feb 01; 14(2):329-336. PubMed ID: 29140753
    [Abstract] [Full Text] [Related]

  • 5. Subunit vaccine against the seven serotypes of botulism.
    Baldwin MR, Tepp WH, Przedpelski A, Pier CL, Bradshaw M, Johnson EA, Barbieri JT.
    Infect Immun; 2008 Mar 01; 76(3):1314-8. PubMed ID: 18070903
    [Abstract] [Full Text] [Related]

  • 6. Recombinant holotoxoid vaccine against botulism.
    Pier CL, Tepp WH, Bradshaw M, Johnson EA, Barbieri JT, Baldwin MR.
    Infect Immun; 2008 Jan 01; 76(1):437-42. PubMed ID: 17967862
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. What next for botulism vaccine development?
    Webb RP, Smith LA.
    Expert Rev Vaccines; 2013 May 01; 12(5):481-92. PubMed ID: 23659297
    [Abstract] [Full Text] [Related]

  • 13. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
    Shone C, Agostini H, Clancy J, Gu M, Yang HH, Chu Y, Johnson V, Taal M, McGlashan J, Brehm J, Tong X.
    Infect Immun; 2009 Jul 01; 77(7):2795-801. PubMed ID: 19398544
    [Abstract] [Full Text] [Related]

  • 14. Deletion mutant comprising 198 residues of BoNT/A toxin receptor binding domain retained gt1b binding property but failed to induce protective antibody response in a mouse model.
    Singh MK, Gupta G, Boopathi M, Gupta P, Chauhan V, Tomar A, Singh L, Dhaked RK.
    Protein Pept Lett; 2012 May 01; 19(5):530-7. PubMed ID: 22486648
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors.
    Yu Y, Yu J, Li N, Wang S, Yu W, Sun Z.
    Vaccine; 2009 Oct 19; 27(44):6148-53. PubMed ID: 19712769
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.